New test helps determine prostate cancer outcome:
This article was originally published in Clinica
Executive Summary
Measuring the ratio of free-floating prostate specific antigen (PSA) to total PSA in the blood could help doctors determine a patient's prognosis following radiotherapy for prostate cancer, according to a Canadian study. Researchers studied 102 men undergoing prostate biopsy around 40 months after radiotherapy for prostate cancer. Their results, published in the July issue of Urology, showed that the ratio of free to total PSA was on average significantly lower in those with positive biopsies (15%) compared with those who had negative biopsies (27%).